INCYTE WKN: 896133 ISIN: US45337C1027 Kürzel: INCY Forum: Aktien Thema: Hauptdiskussion

Ich bin invistiert, Einkauf 69 Euro, 5k

So ruhig hier

Bin gerade eingestiegen

ist hier noch jemand investiert?chancen?danke

Hab nach den Zahlen die erste Position gekauft und gerade die zweite Position

-8% 🙈 trotz guten zahlen?

Der Kurs zeigt in die verkehrte Richtung 😭

Incyte Corp. übertrifft im vierten Quartal mit einem Gewinn je Aktie von $0,93 die Analystenschätzungen von $0,75. Umsatz mit $789,51 Mio. über den Erwartungen von $662,94 Mio. Quelle: Guidants News: 09.02.21, 13:20

Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) https://investor.incyte.com/press-releases/press-releases/2021/Incyte-Announces-Acceptance-and-Priority-Review-of-BLA-for-Retifanlimab-as-a-Potential-Treatment-for-Patients-with-Squamous-Cell-Carcinoma-of-the-Anal-Canal-SCAC/default.aspx

Geht da heute was ?

https://www.businesswire.com/news/home/20201207005129/en/Incyte-Announces-Parsaclisib-Treatment-Results-in-High-Rate-of-Rapid-and-Durable-Responses-in-Patients-with-Relapsed-or-Refractory-B-Cell-Non-Hodgkin-Lymphomas

Incyte EPS misses by $0.53, misses on revenue https://seekingalpha.com/news/3631986-incyte-eps-misses-0_53-misses-on-revenue Incyte (NASDAQ:INCY): Q3 Non-GAAP EPS of $0.23 misses by $0.53; GAAP EPS of -$0.07 misses by $0.57. Revenue of $620.64M (+12.5% Y/Y) misses by $1.84M.

Lilly/Incyte's baricitinib shows additional benefit in hospitalized COVID-19 patients https://seekingalpha.com/news/3623006-lilly-incytes-baricitinib-shows-additional-benefit-in-hospitalized-covidminus-19-patients

Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics https://m.marketscreener.com/news/latest/Nimble-Announces-Strategic-Research-Collaboration-with-Incyte-to-Discover-Novel-Peptide-Based-Therap--31484994/

https://www.businesswire.com/news/home/20200918005082/en/Incyte-Announces-Encouraging-Results-From-Phase-2-Trial-of-Retifanlimab-INCMGA0012-in-Patients-With-Previously-Treated-Advanced-Squamous-Cell-Carcinoma-of-the-Anal-Canal Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal

Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time https://www.marketwatch.com/story/shares-of-lilly-and-incyte-gain-after-late-stage-study-finds-their-arthritis-drug-can-help-reduce-covid-19-recovery-time-2020-09-14